Healthcare Global Enterprises Limited

rs,

Mumbai - 400051, Maharashtra, India BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India Dear Sir/Madam, Subject : Updated Investor Pr

rs 29

Chennai Double Road S h a r e h o l d i n g P a t t e r n a s o f J u n ’ 2 2 Public Shareholders 29% 13% 58% Dr. BS Ajai Kumar and family (1) Established centers were operational before 2017; (2

13%

Double Road S h a r e h o l d i n g P a t t e r n a s o f J u n ’ 2 2 Public Shareholders 29% 13% 58% Dr. BS Ajai Kumar and family (1) Established centers were operational before 2017; (2) Incl

58%

le Road S h a r e h o l d i n g P a t t e r n a s o f J u n ’ 2 2 Public Shareholders 29% 13% 58% Dr. BS Ajai Kumar and family (1) Established centers were operational before 2017; (2) Includes

89%

th in India Under-coverage of Population Indian Cancer Care Industry (INR bn) – Projected Growth 89% 91% CAGR 12% 38% 10% India China UK USA Population coverage by national cancer registries

91%

India Under-coverage of Population Indian Cancer Care Industry (INR bn) – Projected Growth 89% 91% CAGR 12% 38% 10% India China UK USA Population coverage by national cancer registries Incr

12%

der-coverage of Population Indian Cancer Care Industry (INR bn) – Projected Growth 89% 91% CAGR 12% 38% 10% India China UK USA Population coverage by national cancer registries Increasing Can

38%

overage of Population Indian Cancer Care Industry (INR bn) – Projected Growth 89% 91% CAGR 12% 38% 10% India China UK USA Population coverage by national cancer registries Increasing Cancer I

10%

ge of Population Indian Cancer Care Industry (INR bn) – Projected Growth 89% 91% CAGR 12% 38% 10% India China UK USA Population coverage by national cancer registries Increasing Cancer Incide

3%

0 Real Incidences ('000s) Sources: Globacan 2018, ICMR; NCRP Annual Report 2020, Industry Reports 3% 263 3% 1% Affordability Realization 3% Relapse Driven 1% Population Growth Cancer Inci

1%

nces ('000s) Sources: Globacan 2018, ICMR; NCRP Annual Report 2020, Industry Reports 3% 263 3% 1% Affordability Realization 3% Relapse Driven 1% Population Growth Cancer Incidences 151

81%

tion Coverage Low Early-stage Diagnosis in India … …leading to High Mortality to Incidence Ratio 81% 71% 73% 29% 31% 30% 19% 8% 31% 26% 25% 15% 51% 52% 56% 17% 22% 28% 33% 23% 88%

“Although the Company believes that such forward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met.”

“BS Ajai Kumar Executive Chairman Visionary and key driving force of HCG, with an aim to make advanced cancer care accessible Raj Gore Whole-time Director and CEO Seasoned healthcare leader with 20+ years in management across North America, Asia & Africa Abhay Prabhakar Havaldar Non-Executive Independent Director Established General Atlantic’s India Office.”

“The management plans to prudently invest to grow these businesses going forward 21 www .”

“c o m Capital Light Capital Led Successful Playbook of Smart Acquisitions and Driving Sustained Growth Post Integration Time tested and highly replicable model of consistent revenue growth and profitability across geographies Acquisition Year Revenue CAGR(2) Margin Expansion (2) Key Interventions HCG Ahmedabad (Metro City) HCG Cuttack (Non-metro City) 2013(1) c.”

Ref

1

Ref

Regulation 30 and Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Further to the intimation dated September 27, 2022, we are submitting herewith the updated Investor Presentation. Kindly take this on record. Thanking you, For HealthCare Global Enterprises Limited Sunu Manuel Company Secretary & Compliance Officer Encl: a/a. HealthCare Global Enterprises Limited HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489 HEALTHCARE GLOBAL ENTERPRISES LIMITED D I SC USSI ON MATERI AL October 2022 Safe Harbor This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from India, the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This presentation has been prepared by Heal